FIELD: chemistry.
SUBSTANCE: invention refers to practically pure polymorphic forms of A and B N-[({2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridine-1-yl)phenyl] ethyl}-amino)carbonyl]-4-methylbenzolsulphone-amide, to pharmaceutical compositions containing specified polymorphic forms, and also to their application and application of pharmaceutical compositions containing them. Additionally, the invention concerns method of pain management, therapy of inflammation, osteoarthritis or rheumatoid arthritis, as involving introduction of saif polymorphic forms A and B.
EFFECT: new crystal forms of N-[({2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridine-1-yl)phenyl] ethyl}-amino)carbonyl]-4-methylbenzolsulphone-amide are the most stable of the identified forms.
14 cl, 2 tbl, 12 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
| IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING IT AS AN ACTIVE INGREDIENT | 2020 |
|
RU2810973C2 |
| USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
| PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | 2009 |
|
RU2531274C2 |
| NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
| MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
| HETEROCYCLIC IMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF | 2016 |
|
RU2686314C1 |
| THIAZOLINO-2-PYRIDONES WITH CONDENSED RINGS IN COMBINATION WITH A DRUG AGAINST TUBERCULOSIS | 2018 |
|
RU2791467C2 |
| CYCLIC CYANOENONE DERIVATIVES AS KEAP1 MODULATORS | 2021 |
|
RU2822828C1 |
